Skip to content

Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy

Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy (RPVE) in Prostate Cancer (PCA) Patients for Molecular Tumor Marker Analysis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02460861
Acronym
iPROLOGX
Enrollment
279
Registered
2015-06-03
Start date
2011-11-30
Completion date
2015-12-31
Last updated
2015-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Prostate Cancer, Molecular staging, GSTP1, Surgical margins, prostatovesiculectomy

Brief summary

This project is about the detection of occult tumor cells in surgical margins of radical prostatovesiculectomy by analysing the methylation status of Glutathione S-transferase P 1 (GSTP1). After gland excision specimens are obtained from 9 defined areas of the prostatic fossa. The biopsies are divided into two parts. One part used for histopathological analysis and the other part for moleculargenetic analysis. Results will be correlated e.g. with tumor stage, Gleason Score and prostate specific antigen (PSA). The prostate-cancer-negative control group with bladder cancer.

Detailed description

This project is about the detection of occult tumor cells in surgical margins of radical prostatovesiculectomy by analysing the methylation status of Glutathione S-transferase P 1 (GSTP1). After gland excision specimens are obtained from 9 defined areas of the prostatic fossa. The biopsies are divided into two parts. One part used for histopathological analysis and the other part for moleculargenetic analysis. Results will be correlated e.g. with tumor stage, Gleason Score and prostate specific antigen (PSA). The prostate-cancer-negative control group with bladder cancer. DNA ISOLATION DNA from biopsies stored by -80°C was isolated by using innuPREP DNA mini Kit (Analytik Jena, Jena, Germany) following protocol 1 of the manufacturer's instructions. DNA was eluted with 50 µl elution buffer. Concentration and purity were analysed by using Nanodrop 2000. DNA BISULFITE MODIFICATION DNA was modified by using EpiTect Bisulfite Kit (QIAGEN, Hilden, Germany) according to manufacturer's instructions. Samples were eluted once with 20 µl elution buffer. QUANTITATIVE METHYLATION SPECIFIC PCR Methylation status of GSTP1 is analysed by quantitative methylation-specific PCR (Q-MSP) using StepOnePlus Real-Time PCR System and StepOne Software v2.1 from Applied Biosystems (Darmstadt, Germany). Q-MSP was performed in duplicate analysing genes Actin and GSTP1. The primers' and testing probes' sequences used to amplify and detect hypermethylated GSTP1 were: 5'-AgTTgCgCggCgATTTC (forward primer), 5'-gCCCCAATACTAAATCACgACg (reverse primer) and 5'-CggTCgACgTTCggggTgTAgCg (taqman probe), labelled with fluorescence dye FAM. The primers' and testing probes' sequences used to amplify and detect Actin were: 5'-TggTgATggAggAggTTTAgTAAgT (forward primer), 5'-AACCAATAAAACCTACTCCTCCCTTAA (reverse primer),5'-ACCACCACCCAACACACAATAACAAACACA (taqman probe), labelled with fluorescence dye VIC. The Q-MSP was carried out at 50°C for 2 min., 95°C for 15 min. followed by 50 cycles of 95°C for 1s and 60°C for 1 min. As a positive control bisulfite-converted DNA of DU145 and LNCap were used. Blank reactions with destillated water, which replaced DNA, served as negative control (NTC).

Interventions

PROCEDUREbiopsies of the prostatic fossa in Magdeburg

intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg

PROCEDURERPVE

Open Radical prostatovesiculectomy in Magdeburg

PROCEDUREETRARP

Robotassisted Radical prostatovesiculectomy in Gronau

PROCEDURECE

Open cystectomy in Magdeburg/Gronau

PROCEDUREbiopsies of the prostatic fossa in gronau

intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau

Sponsors

St. Antonius Hospital Gronau
CollaboratorOTHER
University of Magdeburg
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

Criteria for patients with prostate adenocarcinoma: Inclusion Criteria * sex: male * diagnosis: prostate adenocarcinoma * treatment: radical prostatovesiculectomy * period of treatment: 11/30/2011 - 10/15/2013

Exclusion criteria

* sex: female * diagnosis: no prostate adenocarcinoma * treatment: no radical prostatovesiculectomy * period of treament: before 11/30/2011 or after 10/15/2013 Criteria for prostate adenocarcinoma negative control group: Inclusion Criteria * sex: male * diagnosis: urothelial carcinoma * treatment: cysto-prostatectomy * period of treament: 12/14/2011 - 02/18/2014

Design outcomes

Primary

MeasureTime frameDescription
Methylation status of GSTP12 yearsMethylation status of GSTP1 is analysed by quantitative methylation-specific PCR (Q-MSP)
Histopathology of prostate fossa biopsies2 yearsHistopathology of prostate fossa biopsies (Prostata cancer positive or negative)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026